Sibylla Biotech S.p.A.

Sibylla Biotech is an early-stage drug discovery company whose primary goal is the identification of small molecule degraders acting against undruggable targets. Sibylla's key differentiator lies in its computational platform, which is a unique enabler of a new class of molecular simulations that consider the vectorial nature of protein folding and the interactions of the nascent chain with the ribosome.
This approach allows Sibylla to rationally design small molecules capable of inducing target degradation by interfering with its folding process. Such folding-interfering degraders can effectively act on undruggable targets. Indeed, an unligandable protein in the native state can become druggable in one of the intermediate conformations of its folding pathway.
Sibylla is currently progressing this new type of degraders towards the preclinical phase. The company’s lead candidate degrades Cyclin D1, a protein involved in different cancers and still considered an undruggable target.